Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Teva Pharmaceutical

    Tag: teva pharmaceutical

    You Searched For "Teva Pharmaceutical"
    Allergan, Endo agree to USD 15 million settlement in major opioid case

    Allergan, Endo agree to USD 15 million settlement in major opioid case

    Medical Dialogues Bureau24 Aug 2019 9:00 AM IST
    Allergan has tentatively agreed to pay $5 million to resolve claims involving its branded opioids, though the deal does not resolve claims involving...
    Oklahoma judge approves Teva Pharma USD 85 million opioid settlement

    Oklahoma judge approves Teva Pharma USD 85 million opioid settlement

    Medical Dialogues Bureau25 Jun 2019 9:00 AM IST
    U.S: An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd (Teva Pharma) resolving claims by...
    Teva Pharma to settle $85 million opioid claims of Oklahoma

    Teva Pharma to settle $85 million opioid claims of Oklahoma

    Medical Dialogues Bureau27 May 2019 9:00 AM IST
    Oklahoma Attorney General Mike Hunter has alleged that JnJ and Teva Pharma, along with OxyContin maker Purdue Pharma LP, carried out deceptive marking...
    Eli Lilly new migraine drug Emgality pulls ahead of Amgen in battle for prescriptions

    Eli Lilly new migraine drug Emgality pulls ahead of Amgen in battle for prescriptions

    Farhat Nasim12 May 2019 9:30 AM IST
    Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly's therapy Emgality claimed the...
    USFDA nod to Teva generic nasal spray-Narcan to treat opioid overdose

    USFDA nod to Teva generic nasal spray-Narcan to treat opioid overdose

    Medical Dialogues Bureau21 April 2019 9:27 AM IST
    The U.S. Food and Drug Administration granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a...
    OxyContin maker Purdue Pharma agrees to settle Oklahoma opioid case: Source

    OxyContin maker Purdue Pharma agrees to settle Oklahoma opioid case: Source

    Farhat Nasim26 March 2019 9:25 AM IST
    U.S: Purdue Pharma LP has agreed to settle a lawsuit by the state of Oklahoma accusing the OxyContin painkiller maker of helping fuel an opioid abuse...
    Novartis to launch epinephrine-rival to EpiPens

    Novartis to launch epinephrine-rival to EpiPens

    Farhat Nasim7 Dec 2018 9:30 AM IST
    New Delhi: Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States,...
    Teva to sell contraceptive brand Paragard in 1.1 billion dollar deal

    Teva to sell contraceptive brand Paragard in 1.1 billion dollar deal

    Ruby Khatun Khatun13 Sept 2017 1:43 PM IST
    Teva Pharmaceutical Industries, on Monday, agreed to sell its contraceptive brand Paragard to a unit of Cooper Cos for $1.1 billion, on a day the...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok